Provided by Tiger Fintech (Singapore) Pte. Ltd.

BEIGENE

155.700
-0.600-0.38%
Volume:5.32M
Turnover:827.32M
Market Cap:216.89B
PE:-42.52
High:159.600
Open:157.900
Low:153.200
Close:156.300
Loading ...

ImmunityBio Partners With BeiGene to Conduct Phase 3 Trial of Lung Cancer Combination Therapy

MT Newswires Live
·
29 Jan

BeiGene Stock Meets 80-Plus RS Rating Benchmark

Blockhead
·
16 Jan

Is BeiGene (NASDAQ:ONC) A Risky Investment?

Simply Wall St.
·
14 Jan

BUZZ-Beigene's HK shares jump most in 2 years on 'positive' earnings outlook

Reuters
·
14 Jan

Stock Track | BeiGene Soars Nearly 7% as Company Forecasts Positive Operating Income for 2025

Stock Track
·
14 Jan

BeiGene Forecasts 'Positive Operating Income' in 2025; Hong Kong Shares Rise 5%

MT Newswires Live
·
14 Jan

JPMorgan Chase & Co's Short Position in Beigene Decreases to 0.69% on Jan 3 From 1.35% - HKEX

THOMSON REUTERS
·
09 Jan

JPMorgan Chase & Co's Long Position in Beigene Decreases to 9.83% on Jan 3 From 10.33% - HKEX

THOMSON REUTERS
·
09 Jan

MAIA Biotechnology Shares Rise After Supply Agreement With BeiGene

Dow Jones
·
08 Jan

BeiGene Gets FDA Approval for Tevimbra in Stomach-Esophagus Junction Cancer

MT Newswires Live
·
27 Dec 2024

BeiGene Stomach-Cancer Treatment Gets FDA Approval, Second in U.S.

Dow Jones
·
27 Dec 2024

BeiGene to Change Ticker Symbol to 'ONC', Reflecting Oncology Commitment

MT Newswires Live
·
23 Dec 2024

BeiGene, Ltd.'s (NASDAQ:BGNE) recent 15% pullback adds to one-year year losses, institutional owners may take drastic measures

Simply Wall St.
·
17 Dec 2024

JPMorgan Chase & Co's Short Position in Shares of Beigene Decreases to 1.66% on Dec. 11 From 2.42% - HKEX

THOMSON REUTERS
·
16 Dec 2024

BeiGene Enters Global Licensing Agreement with CSPC Zhongqi for Experimental Cancer Therapy

MT Newswires Live
·
13 Dec 2024

CSPC Pharmaceutical Group Grants Exclusive License of Cancer Inhibitor to BeiGene Switzerland

MT Newswires Live
·
13 Dec 2024